114 related articles for article (PubMed ID: 11800646)
21. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.
Husemann K; Wolter M; Büschges R; Boström J; Sabel M; Reifenberger G
J Neuropathol Exp Neurol; 1999 Oct; 58(10):1041-50. PubMed ID: 10515227
[TBL] [Abstract][Full Text] [Related]
22. Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome.
Zolota V; Tsamandas AC; Aroukatos P; Panagiotopoulos V; Maraziotis T; Poulos C; Scopa CD
Neuropathology; 2008 Feb; 28(1):35-42. PubMed ID: 18181833
[TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.
Korshunov A; Golanov A
J Neurooncol; 2000 May; 48(1):13-9. PubMed ID: 11026692
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
25. Oligodendroglioma: CD44 as a possible prognostic opportunity.
Buccoliero AM; Caldarella A; Arganini L; Mennonna P; Ammanati F; Taddei A; Taddei GL
Clin Neuropathol; 2003; 22(4):169-75. PubMed ID: 12908752
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 in oligodendroglial neoplasms.
Castilla EA; Prayson RA; Kanner AA; Rybicki LA; Tubbs RR; Vogelbaum MA; Barnett GH
Cancer; 2003 Oct; 98(7):1465-72. PubMed ID: 14508834
[TBL] [Abstract][Full Text] [Related]
27. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia.
He J; Hoang-Xuan K; Marie Y; Leuraud P; Mokhtari K; Kujas M; Delattre JY; Sanson M
Neurology; 2000 Sep; 55(6):867-9. PubMed ID: 10994011
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases.
Dehghani F; Schachenmayr W; Laun A; Korf HW
Acta Neuropathol; 1998 May; 95(5):493-504. PubMed ID: 9600596
[TBL] [Abstract][Full Text] [Related]
29. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
Geiger KD; Stoldt P; Schlote W; Derouiche A
Am J Pathol; 2000 Dec; 157(6):1785-93. PubMed ID: 11106550
[TBL] [Abstract][Full Text] [Related]
30. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
[TBL] [Abstract][Full Text] [Related]
31. Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma.
Morishita A; Masaki T; Yoshiji H; Nakai S; Ogi T; Miyauchi Y; Yoshida S; Funaki T; Uchida N; Kita Y; Funakoshi F; Usuki H; Okada S; Izuishi K; Watanabe S; Kurokohchi K; Kuriyama S
Hepatology; 2004 Sep; 40(3):677-86. PubMed ID: 15349907
[TBL] [Abstract][Full Text] [Related]
32. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status.
Katsetos CD; Del Valle L; Geddes JF; Aldape K; Boyd JC; Legido A; Khalili K; Perentes E; Mörk SJ
J Neuropathol Exp Neurol; 2002 Apr; 61(4):307-20. PubMed ID: 11939586
[TBL] [Abstract][Full Text] [Related]
33. Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study.
Tena-Suck ML; Moreno-Jiménez S; Alonso M; Aguirre-Crux L; Sánchez A
Ann Diagn Pathol; 2008 Oct; 12(5):313-21. PubMed ID: 18774492
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas.
Vaquero J; Zurita M; Coca S; Oya S; Morales C
Surg Neurol; 2000 Sep; 54(3):229-34; discussion 234. PubMed ID: 11118569
[TBL] [Abstract][Full Text] [Related]
35. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling.
Kleinschmidt-DeMasters BK; Hashizumi TL; Sze CI; Lillehei KO; Shroyer AL; Shroyer KR
J Clin Pathol; 1998 Apr; 51(4):284-93. PubMed ID: 9659240
[TBL] [Abstract][Full Text] [Related]
36. Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Bartkova J; Thullberg M; Rajpert-De Meyts E; Skakkebaek NE; Bartek J
Int J Cancer; 2000 Feb; 85(3):370-5. PubMed ID: 10652429
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of oligodendrogliomas.
Lebrun C; Fontaine D; Ramaioli A; Vandenbos F; Chanalet S; Lonjon M; Michiels JF; Bourg V; Paquis P; Chatel M; Frenay M;
Neurology; 2004 May; 62(10):1783-7. PubMed ID: 15159478
[TBL] [Abstract][Full Text] [Related]
38. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
[TBL] [Abstract][Full Text] [Related]
39. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
40. p18INK4c and p27KIP1 are required for cell cycle arrest of differentiated myotubes.
Myers TK; Andreuzza SE; Franklin DS
Exp Cell Res; 2004 Nov; 300(2):365-78. PubMed ID: 15475001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
